BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12474053)

  • 1. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
    Gabri MR; Ripoll GV; Alonso DF; Gómez DE
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
    Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
    Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
    Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
    Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
    Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
    Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
    Dohi T; Nores G; Hakomori S
    Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
    Ravindranath MH; Brazeau SM; Morton DL
    Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.
    Nores GA; Dohi T; Taniguchi M; Hakomori S
    J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
    Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
    Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
    Venier C; Guthmann MD; Fernández LE; Fainboim L
    Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
    Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
    J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of melanoma antigen and its involvement in tumor-escape mechanisms.
    Taniguchi M; Sakatsume M; Harada Y; Nores GA; Hakomori S
    Princess Takamatsu Symp; 1988; 19():247-54. PubMed ID: 2978619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
    Ravindranath MH; Kelley MC; Jones RC; Amiri AA; Bauer PM; Morton DL
    Int J Cancer; 1998 Jan; 75(1):117-24. PubMed ID: 9426699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells.
    Inokuchi J; Momosaki K; Shimeno H; Nagamatsu A; Radin NS
    J Cell Physiol; 1989 Dec; 141(3):573-83. PubMed ID: 2531751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
    Mazorra Z; Mesa C; Fernández A; Fernández LE
    Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential.
    Sawada M; Moriya S; Shineha R; Satomi S; Miyagi T
    Acta Biochim Pol; 1998; 45(2):343-9. PubMed ID: 9821865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.